NCT07105709RECRUITINGanonymous

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 2

Modality

AI-normalized

small molecule

Target

AI-normalized

GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.

Indication / condition

AI-normalized

Alzheimer's Disease

Intervention

Source record

GSK4527226

Source & freshness

Source record

NCT ID

NCT07105709

Original source

ClinicalTrials.gov

Source last updated

Feb 02, 2026

Ingested at

Jun 12, 2026

Internal sync

Jun 12, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT07105709

Title

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

Sponsor

GlaxoSmithKline

Status

RECRUITING

Phase

Phase 2

Condition raw

Alzheimer's Disease

Condition normalized

Alzheimer's Disease

Modality raw

small molecule

Modality normalized

small molecule

Target raw

GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.

Target normalized

GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.

Interventions

GSK4527226

Public preview

Source record

GSK4527226 is positioned within a competitive landscape of Alzheimer's Disease therapies, particularly targeting early-stage patients with mild cognitive impairment and mild dementia. The market for Alzheimer's treatments is substantial, with increasing demand for effective disease-modifying therapies. GSK's collaboration with Alector Inc. may enhance its development capabilities and market reach. The success of this trial could provide GSK with a significant foothold in the Alzheimer's market, which is currently underserved, particularly for early intervention strategies.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT07105709

Status

RECRUITING

Phase

Phase 2

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedFeb 02, 2026

Internal syncJun 12, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT07105709

Indication

Alzheimer's Disease

Modality

small molecule

Target

GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.

Intervention

GSK4527226

Source record